NASDAQ:KNSA - Kiniksa Pharmaceuticals Stock Price, Forecast & News

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) released its earnings results on Monday, October, 28th. The company reported ($0.49) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.72) by $0.23. View Kiniksa Pharmaceuticals' Earnings History.

Kiniksa Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Kiniksa Pharmaceuticals.

4 brokerages have issued 1-year price targets for Kiniksa Pharmaceuticals' stock. Their forecasts range from $18.00 to $35.00. On average, they expect Kiniksa Pharmaceuticals' stock price to reach $26.33 in the next twelve months. This suggests a possible upside of 41.5% from the stock's current price. View Analyst Price Targets for Kiniksa Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kiniksa Pharmaceuticals.

Media stories about KNSA stock have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kiniksa Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals saw a decrease in short interest in January. As of January 15th, there was short interest totalling 1,290,000 shares, a decrease of 7.9% from the December 31st total of 1,400,000 shares. Based on an average daily trading volume, of 277,100 shares, the days-to-cover ratio is currently 4.7 days. Approximately 8.1% of the company's stock are short sold. View Kiniksa Pharmaceuticals' Current Options Chain.

Some companies that are related to Kiniksa Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Genmab A/S (GMAB), Alkermes (ALKS), Allakos (ALLK) and Axsome Therapeutics (AXSM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Agile Therapeutics (AGRX), Exelixis (EXEL), Amarin (AMRN), Clovis Oncology (CLVS), Global Blood Therapeutics (GBT), Nabriva Therapeutics (NBRV), Vanda Pharmaceuticals (VNDA), ACADIA Pharmaceuticals (ACAD), Aduro BioTech (ADRO) and Arrowhead Pharmaceuticals (ARWR).

(KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Kiniksa Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (4.16%), Alyeska Investment Group L.P. (0.71%), State Street Corp (0.41%), Geode Capital Management LLC (0.35%), Fairmount Funds Management LLC (0.30%) and Bank of America Corp DE (0.28%). Company insiders that own Kiniksa Pharmaceuticals stock include Bros Advisors Lp Baker, Cormorant Asset Management, Lp, James E Flynn, John F Paolini and Thomas W Beetham. View Institutional Ownership Trends for Kiniksa Pharmaceuticals.

KNSA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc. and State Street Corp. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include John F Paolini and Thomas W Beetham. View Insider Buying and Selling for Kiniksa Pharmaceuticals.

KNSA stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Fairmount Funds Management LLC, Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, Schonfeld Strategic Advisors LLC, Alyeska Investment Group L.P., Geode Capital Management LLC and Bank of America Corp DE. Company insiders that have bought Kiniksa Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Insider Buying and Selling for Kiniksa Pharmaceuticals.

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KNSA stock can currently be purchased for approximately $18.61.

Kiniksa Pharmaceuticals has a market capitalization of $1.02 billion. The company earns $-103,230,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe.View Additional Information About Kiniksa Pharmaceuticals.

The official website for Kiniksa Pharmaceuticals is http://www.kiniksa.com/.

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected]